Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. Falciparum in Adults Participating in a Malaria Vaccine Clinical Trial

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Nov 20

PMID 19924281

Citations 33

Authors

John N Waitumbi

Samuel B Anyona

Carol W Hunja

Carolyne M Kifude

Mark E Polhemus

Douglas S Walsh

Chris F Ockenhouse

D Gray Heppner

Amanda Leach

Marc Lievens

W Ripley Ballou

Joe D Cohen

Colin J Sutherland

Affiliations

Soon will be listed here.

Abstract

Objective: RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast containing part of the circumsporozoite protein (CSP) sequence of 3D7 strain of Plasmodium falciparum linked to the hepatitis B surface antigen in a hybrid protein. The RTS,S antigen is formulated with GSK Biologicals' proprietary Adjuvant Systems AS02(A) or AS01(B). A recent trial of the RTS,S/AS02(A) and RTS,S/AS01(B) vaccines evaluated safety, immunogenicity and impact on the development of parasitemia of the two formulations. Parasite isolates from this study were used to determine the molecular impact of RTS,S/AS02(A) and RTS,S/AS01(B) on the multiplicity of infection (MOI) and the csp allelic characteristics of subsequent parasitemias.

Design: The distribution of csp sequences and the MOI of the infecting strains were examined at baseline and in break-through infections from vaccinated individuals and from those receiving a non-malarial vaccine.

Setting: The study was conducted in Kombewa District, western Kenya.

Participants: Semi-immune adults from the three study arms provided isolates at baseline and during break-through infections.

Outcome: Parasite isolates used for determining MOI and divergence of csp T cell-epitopes were 191 at baseline and 87 from break-through infections.

Results: Grouping recipients of RTS,S/AS01(A) and RTS,S/AS02(B) together, vaccine recipients identified as parasite-positive by microscopy contained significantly fewer parasite genotypes than recipients of the rabies vaccine comparator (median in pooled RTS,S groups: 3 versus 4 in controls, P = 0.0313). When analyzed separately, parasitaemic individuals in the RTS,S/AS01(B) group, but not the RTS,S/AS02(A) group, were found to have significantly fewer genotypes than the comparator group. Two individual amino acids found in the vaccine construct (Q339 in Th2R and D371 in Th3R) were observed to differ in incidence between vaccine and comparator groups but in different directions; parasites harboring Q339 were less common among pooled RTS,S/AS vaccine recipients than among recipients of rabies vaccine, whereas parasites with D371 were more common among the RTS,S/AS groups.

Conclusions: It is concluded that both RTS,S/AS vaccines reduce multiplicity of infection. Our results do not support the hypothesis that RTS,S/AS vaccines elicit preferential effects against pfcsp alleles with sequence similarity to the 3D7 pfcsp sequence employed in the vaccine construct.

Citing Articles

The Walter Reed Project, Kisumu Field Station: Impact of Research on Malaria Policy, Management, and Prevention.

Sifuna P, Mbinji M, Lucas T, Onyango I, Akala H, Waitumbi J Am J Trop Med Hyg. 2024; 110(6):1069-1079.

PMID: 38653233 PMC: 11154051. DOI: 10.4269/ajtmh.23-0115.

Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?.

Potter G, Callier V, Shrestha B, Joshi S, Dwivedi A, Silva J Malar J. 2023; 22(1):383.

PMID: 38115002 PMC: 10729369. DOI: 10.1186/s12936-023-04802-0.

Malaria Genomics, Vaccine Development, and Microbiome.

Su X, Stadler R, Xu F, Wu J Pathogens. 2023; 12(8).

PMID: 37624021 PMC: 10459703. DOI: 10.3390/pathogens12081061.

Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson's disease.

Verma A, Kommaddi R, Gnanabharathi B, Hirsch E, Ravindranath V J Neural Transm (Vienna). 2023; 130(4):495-512.

PMID: 36820885 DOI: 10.1007/s00702-023-02604-x.

Genetic polymorphism of circumsporozoite protein of Plasmodium falciparum among Chinese migrant workers returning from Africa to Henan Province.

He Z, Zhang Q, Wang D, Hu Y, Zhou R, Qian D Malar J. 2022; 21(1):248.

PMID: 36030242 PMC: 9419638. DOI: 10.1186/s12936-022-04275-7.

References

Escalante A, Grebert H, Isea R, Goldman I, Basco L, Magris M . A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas--XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol. 2002; 125(1-2):83-90. DOI: 10.1016/s0166-6851(02)00216-5. View

Kester K, Cummings J, Ockenhouse C, Nielsen R, Hall B, Gordon D . Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2008; 26(18):2191-202. DOI: 10.1016/j.vaccine.2008.02.048. View

Mackinnon M, Sowa M, Koram K, Nkrumah F, Osei Y, Hill W . Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. Parasitology. 2001; 123(Pt 2):113-23. DOI: 10.1017/s0031182001008162. View

Polhemus M, Remich S, Ogutu B, Waitumbi J, Otieno L, Apollo S . Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One. 2009; 4(7):e6465. PMC: 2714466. DOI: 10.1371/journal.pone.0006465. View

Takala S, Coulibaly D, Thera M, Dicko A, Smith D, Guindo A . Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 2007; 4(3):e93. PMC: 1820605. DOI: 10.1371/journal.pmed.0040093. View

Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P . A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2):86-91. DOI: 10.1056/NEJM199701093360202. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

Farnert A, Rooth I, Svensson , Snounou G, Bjorkman A . Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis. 1999; 179(4):989-95. DOI: 10.1086/314652. View

Kester K, McKinney D, Tornieporth N, Ockenhouse C, Heppner D, Hall T . Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 2001; 183(4):640-7. DOI: 10.1086/318534. View

10.

Kester K, McKinney D, Tornieporth N, Ockenhouse C, Heppner Jr D, Hall T . A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine. 2007; 25(29):5359-66. DOI: 10.1016/j.vaccine.2007.05.005. View

11.

Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, BROWN K . Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 2000; 93(4):369-74. DOI: 10.1016/s0035-9203(99)90120-7. View

12.

Ashley E, White N . Artemisinin-based combinations. Curr Opin Infect Dis. 2005; 18(6):531-6. DOI: 10.1097/01.qco.0000186848.46417.6c. View

13.

Epstein J, Giersing B, Mullen G, Moorthy V, Richie T . Malaria vaccines: are we getting closer?. Curr Opin Mol Ther. 2007; 9(1):12-24. View

14.

. A single agenda needed for malaria. Lancet Infect Dis. 2003; 3(6):317. DOI: 10.1016/s1473-3099(03)00635-2. View

15.

Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C . Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008; 359(24):2533-44. DOI: 10.1056/NEJMoa0807773. View

16.

Mayor A, Saute F, Aponte J, Almeda J, Gomez-Olive F, Dgedge M . Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop Med Int Health. 2003; 8(1):3-11. DOI: 10.1046/j.1365-3156.2003.00968.x. View

17.

Heppner Jr D, Kester K, Ockenhouse C, Tornieporth N, Ofori O, Lyon J . Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005; 23(17-18):2243-50. DOI: 10.1016/j.vaccine.2005.01.142. View

18.

Sacarlal J, Aide P, Aponte J, Renom M, Leach A, Mandomando I . Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis. 2009; 200(3):329-36. DOI: 10.1086/600119. View

19.

Cortes A, Mellombo M, Benet A, Lorry K, Rare L, Reeder J . Plasmodium falciparum: distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea. Exp Parasitol. 2004; 106(1-2):22-9. DOI: 10.1016/j.exppara.2004.01.010. View

20.

Lengeler C . Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev. 2004; (2):CD000363. DOI: 10.1002/14651858.CD000363.pub2. View